HAIFA, Israel – September 13 2022 – GrayMatters Health (GMH), developer of digital self-neuromodulation therapeutics for mental disorders, announced today that it has been named as a Falling Walls Top 25 Venture winner. The award recognizes the most promising science start-ups and innovations and technologies across their respective industries.
As one of the top 25 winners, GMH will present Prism, an investigational medical device to treat PTSD as adjunct to standard of care, at the Falling Walls Science Summit taking place between November 7th-9th. The winner of the pitch round will be awarded the ‘Science Breakthrough of the Year 2022’ award.
“Dedicated to bridging the gaps in mental disorder treatment we are eager to present Prism on the Falling Walls Venture global stage and are honored to be chosen as one of the winners for 2022,” said Oded Kraft, GrayMatters Health Co-Founder and CEO. “Awareness of mental disorders is on the rise, and we expect this to cost the global economy $16 trillion by 2030. Advancing technology to meet the needs of patients remains front and center at GMH as we advance the clinical development of Prism.”
Using a proprietary machine learning technology to create an Electrical-Finger-Print (EFP) of brain-mechanism-specific biomarkers, Prism can train patients employ self neuro-modulation techniques using an interactive audio-visual software. Prism for PTSD, is undergoing clinical investigation in five sites across the United States and Israel to demonstrate its efficacy and safety as a support to standard Post Traumatic Stress Disorder (PTSD) treatments.
The company plans to evaluate the clinical efficacy and safety of Prism for additional mental disorders including Major Depression Disorder (MDD), and Border Personality Disorder (BPD).
About GrayMatters Health
GrayMatters Health (GMH) develops digital self-neuromodulation therapies for mental disorders. GMH uses machine learning technology to create an Electrical-Finger-Print (EFP) of brain-mechanism-specific biomarkers by fusing EEG and fMRI. GMH’s first product, Prism for PTSD, is a non-invasive digital therapy, to be used as an adjunct to PTSD standard of care treatments. Prism for PTSD, is an investigational device under clinical investigation in five sites across the United States and Israel, to demonstrate its efficacy and safety as an adjunct to standard PTSD treatments. The novel technology was developed by Professor Talma Hendler and her team at Tel Aviv Sourasky Medical Center and Tel Aviv University. Learn more by visiting our website https://graymatters.health/ and following us on LinkedIn and Twitter
GrayMatters Health Contact
Oded Kraft, CEO